Clinical Dose Preparation of [177Lu]Lu-DOTA-Pertuzumab Using Medium Specific Activity [177Lu]LuCl3 for Radioimmunotherapy of Breast and Epithelial Ovarian Cancers, with HER2 Receptor Overexpression

Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print.

Source: Cancer Biotherapy and Radiopharmaceuticals - May 16, 2022 Category: Cancer & Oncology Authors: Sreeja Raj Menon Arpit Mitra Avik Chakraborty Megha Tawate Sudeep Sahu Sutapa Rakshit Sujay Gaikwad Geetanjali Dhotre Archana Damle Sharmila Banerjee Source Type: research